Table of Contents

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE

SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2008

COMMISSION FILE NUMBER 0-13251

MEDICAL ACTION INDUSTRIES INC.

(Exact name of Registrant as specified in its charter)

800 Prime Place, Hauppauge, New York 11788

(Address of Principal Executive Offices)

Registrant’s telephone number, including area code:

(631) 231-4600

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Indicate by mark whether the registrant is a shell company (as described in Rule 12b-2 of the Exchange Act.)    Yes  ¨    No  x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. 16,028,161 shares of common stock as of February 5, 2009.

Table of Contents

FORM 10-Q

CONTENTS

2

Table of Contents

Item 1.

MEDICAL ACTION INDUSTRIES INC.

CONSOLIDATED BALANCE SHEETS

(dollars in thousands)

ASSETS

The accompanying notes are an integral part of these financial statements.

3

Table of Contents

Item 1.

MEDICAL ACTION INDUSTRIES INC.

CONSOLIDATED BALANCE SHEETS

(dollars in thousands)

LIABILITIES AND SHAREHOLDERS’ EQUITY

The accompanying notes are an integral part of these financial statements.

4

Table of Contents

Item 1.

MEDICAL ACTION INDUSTRIES INC.

CONSOLIDATED STATEMENTS OF EARNINGS

(dollars in thousands except per share data)

(Unaudited)

The accompanying notes are an integral part of these financial statements.

5

Table of Contents

Item 1.

MEDICAL ACTION INDUSTRIES INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(dollars in thousands)

(Unaudited)

The accompanying notes are an integral part of these financial statements.

6

Table of Contents

Item 1.

MEDICAL ACTION INDUSTRIES INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1. BASIS OF PRESENTATION

The accompanying unaudited interim condensed consolidated financial statements of Medical Action Industries Inc. (“Medical Action” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q for quarterly reports under section 13 or 15(d) of the Securities Exchange Act of 1934. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine month period ended December 31, 2008 are not necessarily indicative of the results that may be expected for the year ended March 31, 2009. For further information, refer to the financial statements and footnotes thereto included in the Company’s annual report for the year ended March 31, 2008.

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts of assets, liabilities, revenues and expenses reported in those financial statements as well as the disclosure of contingent assets and liabilities at the date of the consolidated financial statements. These judgments can be subjective and complex, and consequently, actual results could differ from those estimated. Significant estimates made by the Company include the allowance for doubtful accounts, inventory valuation, fair value of stock based compensation, income taxes, valuation of long-lived assets, accrued sales incentives and rebate reserves. A summary of the Company’s significant accounting policies is identified in Note 1 of the Consolidated Financial Statements in the Company’s Form 10-K for the fiscal year ended March 31, 2008. Users of financial information produced for interim periods are encouraged to refer to the notes contained in the 2008 Annual Report on Form 10-K when reviewing interim financial results. Since March 31, 2008 there have been no changes to the Company’s significant accounting policies or to the assumptions and estimates involved in applying these policies. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation.

Note 2. IMPACT OF RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

Fair Value Measurements

In September 2006, the FASB issued SFAS No. 157, “Fair Value Measurements,” (“SFAS 157”). SFAS 157 defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles, and expands disclosures about fair value measurements. This statement does not require any new fair value measurements; rather, it applies under other accounting pronouncements that require or permit fair value measurements. The provisions of this statement are to be applied prospectively for fiscal years beginning after November 15, 2007, with any transition adjustment recognized as a cumulative-effect

7

Table of Contents

Item 1.

Note 2. (Continued)

adjustment to the opening balance of retained earnings. As of April 1, 2008, we adopted SFAS 157. The adoption of SFAS 157 did not impact our consolidated financial statements in any material respect.

In December 2007, the FASB issued FSP FAS 157-b to defer SFAS 157’s effective date for all non-financial assets and liabilities, except those items recognized or disclosed at fair value on an annual or more frequently recurring basis, until years beginning after November 15, 2008. Derivatives measured at fair value under FAS 133 were not deferred under FSP FAS 157-b. We are assessing the impact, if any, which the adoption of FSP FAS 157-b will have on our consolidated financial position, results of operations and cash flows.

Fair Value Options for Financial Assets and Financial Liabilities

In February 2007, the FASB issued SFAS No. 159, “The Fair Value Option for Financial Assets and Financial Liabilities” (“SFAS 159”), including an amendment of FASB Statement No. 115. SFAS 159 permits an entity to measure certain financial assets and financial liabilities at fair value. The Statement’s objective is to improve financial reporting by allowing entities to mitigate volatility in reported earnings caused by the measurement of related assets and liabilities using different attributes, without having to apply complex hedge accounting provisions. Entities that elect the fair value option will report unrealized gains and losses in earnings at each subsequent reporting date.

The new Statement establishes presentation and disclosure requirements to help financial statement users understand the effect of the entity’s election on its earnings, but does not eliminate disclosure requirements of other accounting standards. SFAS 159 was effective as of the beginning of the first fiscal year that begins after November 15, 2007, and is effective for us as of April 1, 2008. The adoption of SFAS 159 did not impact our consolidated financial statements in any material respect.

Business Combinations

In December 2006, the FASB issued SFAS No. 141 (revised 2007), “Business Combinations,” (“SFAS 141R”) to improve the relevance, representational faithfulness, and comparability of the information that a reporting entity provides in its financial reports about a business combination and its effects. This Statement applies to all transactions or other events in which an entity obtains control of one or more businesses, and combinations achieved without the transfer of consideration. The standard is effective for fiscal years beginning after December 15, 2008. SFAS 141R will have a significant impact on the manner in which we account for future acquisitions beginning in the fiscal year 2010.

Non-Controlling Interests in Consolidated Financial Statements

In December 2007, the FASB issued SFAS No. 160, “Noncontrolling Interests in Consolidated Financial Statements—an amendment of ARB No. 51,” (“SFAS 160”) to improve the relevance, comparability, and transparency of the financial information that a reporting entity provides in its consolidated financial statements. This Statement applies to all entities that prepare consolidated

8

Table of Contents

Item 1.

Note 2. (Continued)

financial statements, except not-for-profit organizations, but will affect only those entities that have an outstanding non-controlling interest in one or more subsidiaries or that deconsolidate a subsidiary. This Statement is effective for fiscal years beginning after December 15, 2008, which for us is the fiscal year beginning April 1, 2009. We are assessing the impact, if any, which the adoption of SFAS 160 will have on our consolidated financial position, results of operations and cash flows.

Disclosures About Derivative Instruments and Hedging Activities

In March 2008, the FASB issued SFAS No. 161, “Disclosures about Derivative Instruments and Hedging Activities,” (“SFAS 161”). This Statement requires enhanced disclosures about an entity’s derivative and hedging activities and thereby improves the transparency of financial reporting. This Statement is effective for financial statements issued for fiscal years and interim periods beginning after November 15, 2008, which for us is the fiscal year beginning April 1, 2009. We are assessing the impact, if any, which the adoption of SFAS 161 will have on our financial statement disclosures.

Note 3. STOCK-BASED COMPENSATION PLANS

During fiscal 1990, the Company’s Board of Directors and stockholders approved a Non-Qualified Stock Option Plan (the “Non-Qualified Option Plan”). The Non-Qualified Option Plan, as amended, authorizes the granting to employees of the Company options to purchase an aggregate of 3,975,000 shares of the Company’s common stock. The options are granted with an exercise price equal to the fair market price of the common stock or at a value that is not less than 85% of the fair market value of the common stock on the date of grant. The options are exercisable in two installments on the second and third anniversary of the date of grant. Options expire ten years from the date of grant unless the employment is terminated, in which event, subject to certain exceptions; the options terminate two months subsequent to date of termination.

In 1994, the Company’s Board of Directors and stockholders approved the 1994 Stock Incentive Plan (the “Incentive Plan”), which, as amended, authorized 3,525,000 shares of the Company’s common stock for awards under the Incentive Plan. The Incentive Plan, which expires in 2015, permits the granting of incentive stock options, shares of restricted stock and non-qualified stock options. All officers and other key employees of the Company and its affiliates are eligible to participate in the Incentive Plan. The Incentive Plan is administered by the Compensation Committee of the Board of Directors, which determines the persons to whom, and the time at which, awards will be granted. In addition, the Compensation Committee will decide the type of awards to be granted and all other related terms and conditions of the awards. The per share exercise price of any option may not be less than the fair market value of a share of common stock at the time of grant. No incentive options have been issued under this plan.

9

Table of Contents

Item 1.

Note 3. (Continued)

The following is a summary of restricted stock activity in our 1994 Stock Incentive Plan for the nine months ended December 31, 2008:

Grants of restricted stock are common stock awards granted to recipients with specified vesting provisions. The restricted stock issued vests based upon the recipients continued service over time (five-year vesting period). The Company estimates the fair value of restricted stock based on the Company’s closing stock price on the date of grant.

In 1996, the Company’s Board of Directors and stockholders approved the 1996 Non-Employee Director Stock Option Plan (the “Director Plan”). The Director Plan which, as amended, authorized 750,000 shares of the Company’s common stock for award under the Director Plan. Under the terms of the Director Plan, which expires in 2015, each non-employee director of the Company will be granted each year an option to purchase 2,500 shares of the Company’s common stock. These options vest immediately and have an exercise price equal to the fair market price of the common stock at the time of grant.

Stock-based compensation cost is measured at the grant date, based on the calculated fair value of the grant, and is recognized as an expense over the service period applicable to the grantee. The service period is the period of time that the grantee must provide services to the Company before the stock-based compensation is fully vested.

Stock-based compensation expense amounted to approximately $278 ($174 after tax) or $.01 per basic and diluted share and $337 ($208 after tax) or $.01 per basic share and diluted share for the three months ended December 31, 2008 and 2007, respectively. Stock-based compensation expense amounted to approximately $984 ($617 after tax) or $.04 per basic and diluted share and $1,198 ($740 after tax) or $.05 per basic and diluted share for the nine months ended December 31, 2008 and 2007, respectively.

10

Table of Contents

Item 1.

Note 3. (Continued)

The following is a summary of the changes in outstanding options for all of the Company’s plans during the nine months ended December 31, 2008:

The fair value of each option grant is estimated on the date of the grant using the Black-Scholes options pricing model. The following weighted average assumptions were used for grants in the nine months ended December 31, 2008 and 2007, respectively: expected volatility of 35.7% and 34.6%; a risk-free interest rate of 3.9% and 4.8% and an expected life of 5.3 years. The expected term of the options is based on evaluations of historical and expected future employee exercise behavior. The risk-free rate is based on the U.S. Treasury rates at the date of grant with maturity dates approximately equal to the life of the grant. The expected volatility is based on the historical volatility of the Company’s stock.

There were no options granted during the three months ended December 31, 2008. The weighted average fair value of options granted was $8.14 for the three months ended December 31, 2007 and $6.28 and $8.62 for the nine months ended December 31, 2008 and 2007, respectively. As of December 31, 2008, there were approximately $2,953 of total SFAS No. 123R unrecognized compensation costs related to nonvested share-based compensation arrangements granted under the Company’s plans. This cost is expected to be recognized over a period of three years.

The following is a summary of the changes in non-vested stock options for the nine months ended December 31, 2008:

11

Table of Contents

Item 1.

Note 4. INVENTORIES

Inventories, which are stated at the lower of cost (first-in, first-out) or market, consist of the following:

On a continuing basis, inventory quantities on hand are reviewed and an analysis of the provision for excess and obsolete inventory is performed based primarily on the Company’s sales history and anticipated future demand. Such provision for excess and obsolete inventory amounted to approximately $783 and $891 at December 31, 2008 and March 31, 2008, respectively.

Note 5. NET INCOME PER SHARE

Basic earnings per share are based on the weighted average number of common shares outstanding without consideration of potential common shares. Diluted earnings per share are based on the weighted average number of common and potential common shares outstanding. The calculation takes into account the shares that may be issued upon exercise of stock options, reduced by the shares that may be repurchased with the funds received from the exercise, based on the average prices during the periods. Excluded from the calculation of earnings per share are options to purchase 1,152,875 and 873,875 shares for the three and nine months ended December 31, 2008 and 256,200 and 232,700 shares for the three and nine months ended December 31, 2007, as their inclusion would not have been dilutive.

12

Table of Contents

Item 1.

Note. 5 (continued)

The following table sets forth the computation of basic and diluted earnings per share for the three and nine months ended December 31, 2008 and 2007, respectively.

Note 6. SHAREHOLDERS’ EQUITY

There were no stock options exercised during the three months ended December 31, 2008. For the nine months ended December 31, 2008, 7,500 stock options were exercised by a board member of the Company in accordance with the Company’s 1996 Non-Employee Director Stock Option Plan. The exercise price of the options exercised ranged from $10.89 per share to $12.54 per share for the nine months ended December 31, 2008. The net cash proceeds from these exercises were $88 for the nine months ended December 31, 2008.

For the three and nine months ended December 31, 2007, 30,435 and 206,450 stock options, respectively were exercised by employees of the Company in accordance with the Company’s 1989 Non-Qualified Stock Option Plan and 1994 Stock Incentive Plan. The exercise price of the options exercised ranged from $8.50 per share to $11.93 per share for the three months ended December 31, 2007 and $1.92 per share to $11.93 per share for the nine months ended December 31, 2007. The net cash proceeds from these exercises were $272 and $1,193 for the three and nine months ended December 31, 2007, respectively.

13

Table of Contents

Item 1.

Note 7. ACQUISITION

On October 17, 2006, the Company acquired, through one of its subsidiaries, the membership interest of Medegen Medical Products (“Medegen” or “MMP”). Medegen is in the business of manufacturing and distributing disposable plastic products for the medical and laboratory markets. MMP markets its products primarily under the trade names Medegen and Vollrath. The purchase price for the assets acquired including related closing costs was approximately $80,497.

During the course of the Company’s evaluation of the acquisition of MMP, the Company determined that it would shut down its Northglenn, Colorado manufacturing facility and relocate the operations into its Gallaway, Tennessee manufacturing facility. The primary reasons for the plant consolidation was as follows: redundancy of operations; elimination of inter-plant freight costs; increase of manufacturing efficiency and reduction of manufacturing costs. In connection with the consolidation, the Company expects to incur approximately $2,687 of restructuring costs of which $974 is related to severance and $1,713 is related to the shutdown of its Northglenn, Colorado facility and relocation of machinery and equipment and certain employees. The $2,687 was recorded as goodwill and accrued liabilities. During the nine months ended December 31, 2008 the Company incurred approximately $1,551 of expenses in connection with this consolidation leaving a balance of $71 in accrued liabilities. The Company is no longer operating from the Northglenn, Colorado facility and all related operations have been relocated to the Gallaway, Tennessee facility.

Note 8. LONG-TERM DEBT

On October 17, 2006, the Company entered into a credit agreement with certain lenders and a bank acting as administration agent for the lenders (the “Credit Agreement”). The Credit Agreement, as most recently amended on September 30, 2008, provides for borrowing of $85,000 and is divided into two types of borrowing facilities, (i) a term loan with a principal amount of $65,000, and (ii) revolving credit loans, which amounts may be borrowed, repaid and re-borrowed up to $20,000. The term loan is payable in quarterly installments as follows: $3,250 for each installment date from March 31, 2007 through June 30, 2008, $250 for each installment date from September 30, 2008 through March 31, 2009, $1,625 for each installment date from June 30, 2009 through March 31, 2010, $3,250 for each installment date from June 30, 2010 through March 31, 2011, $5,325 for each installment date from June 30, 2011 through September 30, 2011 and the remaining principal amount outstanding is due on December 31, 2011. As of December 31, 2008, $41,000 is outstanding on the term loan and $13,500 is outstanding on the revolving credit loans. The Company’s availability under the revolving credit loans amounts to $6,500 as of December 31, 2008.

Both the term loan and revolving credit loans bear interest at the “alternate base rate” plus the “applicable margin” or at the Company’s option the “LIBOR rate” plus the applicable margin. The alternate base rate shall mean a rate per annum equal to the greater of (a) the Prime rate or (b) the Base CD rate in effect on such day plus 1% and (c) the Federal Funds Effective Rate in effect on such day plus  ¹/2 of 1%. Applicable margin shall mean with respect to an adjusted LIBOR loan a range of 75 basis points to 150 basis points. With respect to an alternate base rate loan, the applicable margin shall range from 0 basis points to 50 basis points. Effective September 30, 2008, applicable margin shall mean with respect to an adjusted LIBOR loan a range of 200 basis points to

14

Table of Contents

Item 1.

Note 8. (Continued)

300 basis points. With respect to an alternate base rate loan, the applicable margin shall range from 25 basis points to 125 basis points. The rates for both LIBOR and alternate base rate loans are established quarterly based upon certain agreed upon financial ratios. During the nine months ended December 31, 2008, the average interest rates on the term and revolving credit loans approximated 4.2% and 4.8%, respectively. Borrowings under this agreement are collateralized by all the assets of the Company, and the agreement contains certain restrictive covenants, which, among other matters, impose limitations with respect to the incurrence of liens, guarantees, merger, acquisitions, capital expenditures, specified sales of assets and prohibits the payment of dividends. The Company is also required to maintain various financial ratios which will be measured quarterly. As of December 31, 2008, the Company is in compliance with all such covenants and financial ratios.

In July 1997, the Company acquired land and an existing building located in Arden, North Carolina (the “Arden Facility”). The purchase price for the Arden Facility was $2,900, which was paid at closing. The acquisition of the Arden Facility was financed with the proceeds from the issuance and sale by The Buncombe County Industrial Facilities and Pollution Control Financing Authority of its $5,500 Industrial Development Revenue Bonds (Medical Action Industries Inc. Project), Series 1997 (the “Bonds”). Interest on the Bonds is payable on the first business day of each January, April, July and October commencing October, 1997 and installments of $90 commencing October 1, 1998 and ending July 1, 2013. Principal payments are due and payable in 60 consecutive quarterly installments of $90 commencing October 1, 1998 and ending July 1, 2013 with a final maturity payment of $190. The Bonds bear interest at a variable rate, determined weekly. The average interest rate on the Bonds during the nine months ended December 31, 2008 approximated 2.6%. The remaining principal of the Bonds at December 31, 2008 was $1,810.

Note 9. OTHER MATTERS

The Company is involved in two (2) product liability cases. While the results of these lawsuits cannot be predicted with certainty, management does not expect that the ultimate liabilities, if any, will have a material adverse effect on the financial position or results of operations of the Company and are covered by insurance.

15

Table of Contents

Item 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statement

This report on Form 10-Q contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include plans and objectives of management for future operations, including plans and objectives relating to the future economic performance and financial results of the Company. The forward-looking statements relate to (i) the expansion of the Company’s market share, (ii) the Company’s growth into new markets, (iii) the development of new products and product lines to appeal to the needs of the Company’s customers, (iv) the retention of the Company’s earnings for use in the operation and expansion of the Company’s business and (v) the ability of the Company to avoid information technology system failures which could disrupt the Company’s ability to function in the normal course of business by potentially causing delays or cancellation of customer orders, impeding the manufacture or shipment of products, or resulting in the unintentional disclosure of customer or Company information.

Important factors and risks that could cause actual results to differ materially from those referred to in the forward-looking statements include, but are not limited to, the effect of economic and market conditions, the impact of the consolidation throughout the healthcare supply chain, volatility of raw material costs, volatility in oil prices, foreign currency exchange rates, the impact of healthcare reform, opportunities for acquisitions and the Company’s ability to effectively integrate acquired companies, the ability of the Company to maintain its gross profit margins, the ability to obtain additional financing to expand the Company’s business, the failure of the Company to successfully compete with the Company’s competitors that have greater financial resources, the loss of key management personnel or the inability of the Company to attract and retain qualified personnel, the impact of current or pending legislation and regulation, as well as the risks described from time to time in the Company’s filings with the Securities and Exchange Commission, which include this report on Form 10-Q and the Company’s annual report on Form 10-K for the year ended March 31, 2008.

The forward-looking statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause the actual results, performance and/or achievements of the Company to differ materially from any future results, performance or achievements, express or implied, by the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, and that in light of the significant uncertainties inherent in forward-looking statements; the inclusion of such statements should not be regarded as a representation by the Company or any other person that the objectives or plans of the Company will be achieved.

All amounts presented in our Management’s Discussion and Analysis of Financial Condition and Results of Operations are in thousands, except share and per share data.

16

Table of Contents

Item 2.

Three Months ended December 31, 2008 compared to Three Months ended December 31, 2007

Overview

The following table sets forth certain operational data and operational data as a percentage of net sales for the periods indicated:

The Company’s revenue decreased by $3,903 or 5.1% to $71,995 and its net income decreased by $3,491 or 95.7% to $157 for the quarter ended December 31, 2008 over the quarter ended December 31, 2007. The decrease in revenue is comprised of net unit volume decreases of $5,435, which was partially offset by net price/sales mix increases of $1,532.

The net unit volume decreases were primarily from losses in patient bedside utensils, operating room disposables and sterilization products (predominantly patient aids, which are principally comprised of crutches and disposable operating room towels), laboratory products, and specimen containers. Patient bedside utensils experienced a $2,659 decline in sales volume as a result of lower unit volume sales. Management believes that the decline is attributable to competitive pressures, the effect of customers’ management of inventory balances in reaction to current economic conditions, back order positions and the termination of a supply contract. A significant component of the Company’s net unit volume decreases in patient aids resulted from the Company’s inability to negotiate acceptable price increases on crutches to a major customer and the Company’s unwillingness to continue to provide these crutches at current pricing levels. This resulted in a decline of approximately $1,127 in net sales with only a negligible impact on profitability for the three months ended December 31, 2008 compared to the three months ended December 31, 2007. These net unit volume declines were partially offset by volume increases primarily from greater domestic penetration of our minor procedure kits and trays product line.

The price/sales mix increases were primarily from increased average selling prices of our minor procedure kits and trays, containment systems for medical waste and specimen containers product lines. The increase in average selling prices of certain containment systems for medical waste and specimen container products was due primarily to price increases implemented to recover a portion of the increases in plastic resin (the primary raw material utilized in the manufacture of these products). The increase in average selling prices of our minor procedure kits and trays products was the result of a shift in sales mix and due to an increase in sales of kits containing enhanced components.

17

Table of Contents

Item 2.

Containment systems for medical waste and the product lines added as a result of the acquisition of the membership interest of Medegen Medical Products (“Medegen” or “MMP”) on October 17, 2006, represents approximately 50% of the Company’s revenue. The primary raw material utilized in the manufacture of these product lines is plastic resin. In recent years, world events have continued to cause the cost of plastic resin to increase and be extremely volatile. During the three months ended December 31, 2008, the Company experienced a decline in the cost of resin as measured against increases in resin costs incurred since the acquisition of MMP. The Company anticipates that such volatility may continue in the future as evidenced by increases in resin costs, incurred subsequent to December 31, 2008. A significant portion of the Company’s remaining revenue is derived from products sourced from foreign suppliers based in China. The costs associated with sourcing from these suppliers have increased as a result of inflationary trends, primarily on the cost of raw materials and labor, and the effect of the weakening US dollar versus the Chinese Yuan. Although the US dollar has recently been stable against the Chinese Yuan, the Company anticipates a further weakening of the US dollar versus the Chinese Yuan and a continuation of inflationary trends within China.

The Company has been able, from time to time, to increase selling prices for certain of these products to recover a portion of the increased cost. However, the Company is unable to give any assurance that it will be able to pass along future cost increases to its customers, if necessary.

The Company has entered into agreements with many of the major group purchasing organizations (“GPO”). These agreements, which expire at various times over the next several years, in most cases, can be terminated typically on ninety (90) days advance notice and do not contain minimum purchase requirements. The Company to date has been able to achieve significant compliance to their respective member hospitals. The termination of any of these agreements may result in the significant loss of business.

During the quarter ended June 30, 2008, the Company elected to exercise the ninety (90) day advanced notice termination provisions within one of its GPO agreements, under which the Company supplies disposable operating room towels and laparotomy sponges. The termination of the agreement with the aforementioned GPO amounts to less than 2% of the Company’s net sales and has resulted from the Company’s inability to negotiate acceptable price increases with the GPO and the Company’s unwillingness to continue to provide products to the GPO members at current pricing levels. Although net sales have not been significantly impacted by this termination, the Company cannot predict the future effects on its financial results from such termination.

Gross profit decreased principally as a result of; continued inefficiencies incurred at our Gallaway, Tennessee manufacturing facility, increases in the cost of products sourced from foreign vendors, a decline in sales volume, increases in resin costs, which, in total, exceeded the increase in gross profit resulting from increased average selling prices and a change in the mix of products sold and decreased freight costs.

18

Table of Contents

Item 2.

Results of Operations

The following table sets forth the major sales variance components for the quarter ended December 31, 2008 versus December 31, 2007:

Net sales for the three months ended December 31, 2008 decreased $3,903 or 5.1% to $71,995 from $75,898 for the three months ended December 31, 2007.

The following table sets forth the components of the decrease in net sales as well as percent increases or decreases in unit sales and average selling prices by significant product classes for the three months ended December 31, 2008 compared to the three months ended December 31, 2007:

Management believes that the fluctuations in units sold are predominantly the result of our ability, or inability, to increase penetration within the domestic market, subject to the recent impact of back orders resulting from manufacturing inefficiencies in our Tennessee facility, as well as the impact of general economic conditions within our markets. The increases in average selling prices are primarily due to price increases implemented to recover a portion of the increases in plastic resin and increases in acquisition costs from foreign suppliers.

Gross profit for the three months ended December 31, 2008 decreased $6,653 or 39.8% to $10,083 from $16,736 for the three months ended December 31, 2007. Gross profit as a percentage of net sales for the three months ended December 31, 2008 decreased to 14.0% from 22.1% for the three months ended December 31, 2007. Gross profit decreased as a result of inefficiencies incurred at our Tennessee manufacturing facility of approximately $2,262, declines in unit volume of approximately $1,964, higher resin prices of approximately $1,964, increased costs of products sourced from foreign suppliers, principally from China, of approximately $1,785,

19

Table of Contents

Item 2.

increased operating expenses in our West Virginia and North Carolina manufacturing facilities and the transfer of certain administrative processes to manufacturing overhead of approximately $830. These decreases were partially offset by an increase of approximately $1,532 resulting from higher average selling prices and changes in the mix of products sold and decreased outbound freight costs to customers of approximately $607.

Many of the Company’s products are produced from petroleum derived raw materials such as plastic resin. The Company also bears the cost of both inbound and outbound freight shipments of raw materials and finished products, which are significantly impacted by the cost of oil. The cost of crude oil has declined significantly from its peak levels reached during the month of July 2008. The cost of plastic resin has begun to decline, however, the benefits to the Company from lower plastic resin costs will not be experienced until the three months ended March 31, 2009 as much of the resin that was purchased during the months of June and July 2008 was used in production during the three months ended December 31, 2008.

The volatility associated with resin costs and product acquisition costs from foreign suppliers may continue for the foreseeable future. In the past, we have been able, from time to time, to increase selling prices for certain products subject to such cost volatility as a means to recover a portion of the increases. However, we are unable to give any assurance that we will be successful in passing along future cost increases to our customers, if deemed necessary.

The major causes of the manufacturing inefficiencies were equipment productivity issues in our Tennessee plant and other inefficiencies associated with the consolidation of the MMP manufacturing facilities. The inefficiencies have resulted in backorders and other fulfillment issues on certain products. Management anticipates reductions in these inefficiencies during the remainder of the 2009 fiscal year. However, no assurance can be given that the backorders and order fulfillment issues will not result in the loss of business.

The following table sets forth sales, cost of sales and selling, general and administrative expense data for the periods indicated:

Selling, general and administrative expenses for the three months ended December 31, 2008 decreased 11.5% to $8,886 from $10,046 for the three months ended December 31, 2007. As a percentage of net sales, selling, general and administrative expenses decreased to 12.3% for the three months ended December 31, 2008 from 13.2% for the three months ended December 31, 2007. The decrease in

20

Table of Contents

Item 2.

selling, general and administrative expenses was primarily due to decreased salary and related expenses as a result of increased efficiencies due to the consolidation of certain administrative functions from the Tennessee facility into its Hauppauge, New York corporate headquarters and transfer of certain administrative processes into cost of goods sold also as a result of the consolidation of the facilities and a decrease in bonuses as a result of the Company not meeting certain earnings targets. These decreases were partially offset by an increase in personnel which management believes will facilitate future growth and efficiencies.

Distribution expenses increased $128 to $1,918 for the three months ended December 31, 2008 compared to $1,790 for the three months ended December 31, 2007. The increase in distribution expenses was primarily due to increased labor costs, primarily temporary labor and overtime expenses, caused by backorders resulting from the manufacturing inefficiencies, as previously explained. Sales and Marketing expenses decreased $291 to $4,855 for the three months ended December 31, 2008 compared to $5,146 for the three months ended December 31, 2007. The decrease in Sales and Marketing expenses is primarily due to a decrease in bonuses as a result of the Company not meeting certain earnings targets. General and Administrative expenses decreased $998 to $2,113 for the three months ended December 31, 2008 compared to $3,111 for the three months ended December 31, 2007. The decrease in General and Administrative expenses is primarily due to a decrease in bonuses as result of the Company not meeting certain earnings targets, as well as a decrease in outside consulting fees.

Interest expense for the three months ended December 31, 2008 increased to $945 from $826 for the three months ended December 31, 2007. The increase in interest expense was primarily due to a net increase in the average principal loan balances outstanding partially offset by a decrease in interest rates during the quarter ended December 31, 2008 as compared to the quarter ended December 31, 2007. The increase in principal loan balances were primarily due to a decline in net cash provided by operating activities and an increase in investing activities, which were primarily comprised of equipment purchases in our Tennessee facility and renovations to our new corporate headquarters.

Nine Months ended December 31, 2008 compared to Nine Months ended December 31, 2007

Overview

The following table sets forth certain operational data and operational data as a percentage of net sales for the periods indicated:

21

Table of Contents

Item 2.

The Company’s revenue increased by $4,785 or 2.2% to $223,214 and its net income decreased by $7,245 or 69.5% to $3,183 for the nine months ended December 31, 2008 over the nine months ended December 31, 2007. The increase in revenue was primarily due to net price/sales mix increases of $8,395, partially offset by a decline in net unit volume of $3,610.

The price/sales mix increases were primarily from increased average selling prices of our minor procedure kits and trays, patient bedside utensils and containment systems for medical waste product lines. The increase in average selling prices of our minor procedure kits and trays products was the result of a shift in sales mix and due to an increase in sales of kits containing enhanced components. The increase in average selling prices of certain patient bedside utensils and containment systems for medical waste products was due primarily to price increases implemented to recover a portion of the increases in plastic resin (the primary raw material utilized in the manufacture of these products).

The net unit volume decreases were primarily from losses in patient bedside utensils, operating room disposables and sterilization products (predominantly patient aids, which are principally comprised of crutches and disposable operating room towels), specimen containers and laboratory products. Patient bedside utensils experienced an $835 decline in sales volume as a result of lower unit volume sales. Management believes that the decline is attributable to competitive pressures, the effect of customers’ management of inventory balances in reaction to current economic conditions, back order positions and the termination of a supply contract. A significant component of the Company’s net unit volume decreases in patient aids resulted from the Company’s inability to negotiate acceptable price increases on crutches to a major customer and the Company’s unwillingness to continue to provide these crutches at current pricing levels. This resulted in a decline of approximately $2,258 in net sales with only a negligible impact on profitability for the nine months ended December 31, 2008 compared to the nine months ended December 31, 2007. These net unit volume declines were partially offset by volume increases primarily from greater domestic penetration of our minor procedure kits and trays and protective apparel product lines.

Containment systems for medical waste and the product lines added as a result of the acquisition of the membership interest of Medegen Medical Products (“Medegen” or “MMP”) on October 17, 2006, represents approximately 50% of the Company’s revenue. The primary raw material utilized in the manufacture of these product lines is plastic resin. In recent years, world events have continued to cause the cost of plastic resin to increase and be extremely volatile. During recent months, the Company experienced a decline in the cost of resin as measured against increases in resin costs incurred since the acquisition of MMP. The Company anticipates that such volatility may continue in the future as evidenced by decreases in resin costs incurred subsequent to December 31, 2008. A significant portion of the Company’s remaining revenue is derived from products sourced from foreign suppliers based in China. The costs associated with sourcing from these suppliers have increased as a result of inflationary trends, primarily on the cost of raw materials and labor, and the effect of the weakening US dollar versus the Chinese Yuan. Although the US dollar has recently been stable against the Chinese Yuan, the Company anticipates a further weakening of the US dollar versus the Chinese Yuan and a continuation of inflationary trends within China.

22

Table of Contents

Item 2.

The Company has been able, from time to time, to increase selling prices for certain of these products to recover a portion of the increased cost. However, the Company is unable to give any assurance that it will be able to pass along future cost increases to its customers, if necessary.

The Company has entered into agreements with many of the major group purchasing organizations (“GPO”). These agreements, which expire at various times over the next several years, in most cases, can be terminated typically on ninety (90) days advance notice and do not contain minimum purchase requirements. The Company to date has been able to achieve significant compliance to their respective member hospitals. The termination of any of these agreements may result in the significant loss of business.

During the quarter ended June 30, 2008, the Company elected to exercise the ninety (90) day advanced notice termination provisions within one of its GPO agreements, under which the Company supplies disposable operating room towels and laparotomy sponges. The termination of the agreement with the aforementioned GPO amounts to less than 2% of the Company’s net sales and has resulted from the Company’s inability to negotiate acceptable price increases with the GPO and the Company’s unwillingness to continue to provide products to the GPO members at current pricing levels. Although net sales have not been significantly impacted by this termination, the Company cannot predict the future effects on its financial results from such termination.

Gross profit decreased principally as a result of; continued inefficiencies incurred at our Gallaway, Tennessee manufacturing facility, increases in resin costs, increases in the cost of products sourced from foreign vendors, and higher freight costs which, in total exceeded the increase in gross profit resulting from higher unit sales, increased average selling prices and a change in the mix of products sold.

Results of Operations

The following table sets forth the major sales variance components for the nine months ended December 31, 2008 versus December 31, 2007:

Net sales for the nine months ended December 31, 2008 increased $4,785 or 2.2% to $223,214 from $218,429 for the nine months ended December 31, 2007.

23

Table of Contents

Item 2.

The following table sets forth the components of the increase in net sales as well as percent increases or decreases in unit sales and average selling prices by significant product classes for the nine months ended December 31, 2008 compared to the nine months ended December 31, 2007:

Management believes that the fluctuations in units sold are predominantly the result of our ability, or inability, to increase penetration within the domestic market, subject to the recent impact of back orders resulting from manufacturing inefficiencies in our Tennessee facility. The increases in average selling prices are primarily due to price increases implemented to recover a portion of the increases in plastic resin and increases in acquisition costs from foreign suppliers.

Gross profit for the nine months ended December 31, 2008 decreased $13,882 or 27.6% to $36,405 from $50,287 for the nine months ended December 31, 2007. Gross profit as a percentage of net sales for the nine months ended December 31, 2008 decreased to 16.3% from 23.0% for the nine months ended December 31, 2007. Gross profit decreased as a result of inefficiencies incurred at our Tennessee manufacturing facility of approximately $6,132, higher resin prices of approximately $6,092, increased costs of products sourced from foreign suppliers, principally from China of approximately $5,097, increased operating expenses in our West Virginia and North Carolina manufacturing facilities and the transfer of certain administrative processes to manufacturing overhead of approximately $2,578, approximately $1,425 as a result of decreases in unit volume and increased outbound freight costs to customers of approximately $952. These decreases were partially offset by an increase of approximately $8,395 resulting from higher average selling prices and changes in the mix of products sold.

Many of the Company’s products are produced from petroleum derived raw materials such as plastic resin. The Company also bears the cost of both inbound and outbound freight shipments of raw materials and finished products, which are significantly impacted by the cost of oil. The cost of crude oil has declined significantly from its peak levels reached during the month of July 2008. The cost of plastic resin has begun to decline, however, the benefits to the Company from lower plastic resin costs will not be experienced until the three months ended March 31, 2009 as much of the resin that was purchased during the months of June and July 2008 was used in production during the three months ended December 31, 2008.

The volatility associated with resin costs and product acquisition costs from foreign suppliers may continue for the foreseeable future. In the past, we have been able, from time to time, to increase selling prices for certain products subject to such cost volatility as a means to recover a portion of the increases. However, we are unable to give any assurance that we will be successful in passing along future cost increases to our customers, if deemed necessary.

24

Table of Contents

Item 2.

The major causes of the manufacturing inefficiencies were equipment productivity issues in our Tennessee plant and other inefficiencies associated with the consolidation of the MMP manufacturing facilities. The inefficiencies have resulted in backorders and other fulfillment issues on certain products. Additionally, freight expenses have increased due to the backorder and order fulfillment issues and freight carrier fuel surcharges. Management anticipates reductions in these inefficiencies during the 2009 fiscal year. However, no assurance can be given that the backorders and order fulfillment issues will not result in the loss of business.

The following table sets forth sales, cost of sales and selling, general and administrative expense data for the periods indicated:

Selling, general and administrative expenses for the nine months ended December 31, 2008 decreased 4.7% to $29,270 from $30,700 for the nine months ended December 31, 2007. As a percentage of net sales, selling, general and administrative expenses decreased to 13.1% for the nine months ended December 31, 2008 from 14.1% for the nine months ended December 31, 2007. The decrease in selling, general and administrative expenses was primarily due to decreased salary and related expenses as a result of increased efficiencies due to the consolidation of certain administrative functions from the Tennessee facility into its Hauppauge, New York corporate headquarters and transfer of certain administrative processes into cost of goods sold also as a result of the consolidation of the facilities and a decrease in bonuses as a result of the Company not meeting certain earnings targets. These decreases were partially offset by an increase in personnel which management believes will facilitate future growth and efficiencies.

Distribution expenses increased $1,136 to $5,955 for the nine months ended December 31, 2008 compared to $4,819 for the nine months ended December 31, 2007. The increase in distribution expenses was primarily due to increased labor costs, primarily temporary labor and overtime expenses, caused by backorders resulting from the manufacturing inefficiencies, as previously explained. Sales and Marketing expenses decreased $442 to $14,955 for the nine months ended December 31, 2008 compared to $15,396 for the nine months ended December 31, 2007. The decrease in Sales and Marketing expenses is primarily due to a decrease in sales commissions, as a result of not meeting certain targets, and a decrease in bonuses as result of the Company not meeting

25

Table of Contents

Item 2.

certain earnings targets. General and Administrative expenses decreased $2,124 to $8,361 for the nine months ended December 31, 2008 compared to $10,485 for the nine months ended December 31, 2007. The decrease in General and Administrative expenses is primarily due to a decrease in salaries and related benefits as a result of the consolidation of administrative processes into cost of goods sold, as explained above, as well as a decrease in legal and outside consulting fees. These decreases were partially offset by an increase in recruitment fees as a result of the hiring of personnel as well as increases in general insurances.

Interest expense for the nine months ended December 31, 2008 decreased to $2,061 from $2,781 for the nine months ended December 31, 2007. The decrease in interest expense was attributable to a decrease in interest rates and a net decrease in the average principal loan balances outstanding during the nine months ended December 31, 2008 as compared to the nine months ended December 31, 2007.

Liquidity and Capital Resources

The following table sets forth certain liquidity and capital resources data for the periods indicated:

The Company had working capital of $40,226 with a current ratio of 2.4 at December 31, 2008 as compared to working capital of $25,137 with a current ratio of 1.6 at March 31, 2008. Total borrowings outstanding were $56,379 with a debt to equity ratio of .47 at December 31, 2008 as compared to $47,906 with a debt to equity ratio of .41 at March 31, 2008.

The Company has used its cash and credit facilities during the nine months ended December 31, 2008 to fund; working capital requirements, the acquisition of capital equipment within its manufacturing facilities and the renovation of a building for use as its new corporate headquarters. As discussed, our operations, and in turn our working capital, have been impacted by the rising costs of

26

Table of Contents

Item 2.

resin and products sourced from overseas suppliers as well as operating inefficiencies in our Gallaway, Tennessee manufacturing facility and reduced sales during the quarter ended December 31, 2008. Management determined that scheduled payments to amortize our term loans would likely be affected by borrowings under our revolving credit agreement. It is management’s intent to maintain as much borrowing capacity as practical under our revolving credit agreement to support future working capital requirements. Accordingly, management amended the terms of the Company’s credit agreements (as defined herein) on September 30, 2008. Prior to the amendment the current portion of long term debt associated with our term loan as of March 31, 2008 was $13,000. The amendment, which among other modifications, decreased our current portion of long term debt associated with our term loan as of December 31, 2008 to $5,125. This change in the current portion of long term debt increased working capital by $7,875.

While management believes that the company has excellent relationships with its lenders, we believe that recent volatility in global credit markets make it unlikely that the Company would be able to affect future amendments to its credit agreements relating to scheduled term loan amortization or increasing the availability under our revolving credit agreement in the near term.

Management further believes that the lenders which are participating in our credit facilities, while being negatively impacted by the volatility in global credit markets, will be able to continue to meet their obligations under our credit facilities.

Net cash provided by operating activities during the nine months ended December 31, 2008 consisted primarily of income from operations, depreciation and amortization, and decreases in accounts receivable and prepaid income taxes. These increases were partially offset by increases in inventories, prepaid expenses and other current assets and a decrease in accounts payable.

The Company has financed its operations primarily through cash flows from operations and borrowings from its existing credit facilities. At December 31, 2008 the Company had a cash balance of $4,338 compared to $2,104 at March 31, 2008. The Company’s operating activities provided cash of $5,012 for the nine months ended December 31, 2008 as compared to $14,115 provided during the nine months ended December 31, 2007.

The increase in inventories was primarily due to increased costs, inventory builds in anticipation of Chinese New Year and a decline in sales for the quarter ended December 31, 2008. Management expects to reduce these inventory levels during the quarter ended March 31, 2009. The decrease in accounts receivable at December 31, 2008 was due to the timing of cash receipts occurring in the normal course of business at the end of the quarter when compared to the quarter ended March 31, 2008. The increase in prepaid expenses and other current assets was due to payments for insurance policies which commenced April 1, 2008. The decrease in accounts payable was due to inventory purchasing strategies and the timing of payments.

Investing activities used net cash of $11,339 and $4,625 for the nine months ended December 31, 2008 and December 31, 2007, respectively. Approximately $10,417 of total investing activities during the nine months ended December 31, 2008 was related to the Company’s purchases of property, plant and equipment predominately for its Tennessee manufacturing facility as well as renovations to the Company’s new corporate headquarters.

27

Table of Contents

Item 2.

Financing activities provided net cash of $8,561 for the nine months ended December 31, 2008 compared to net cash of $9,107 used during the nine months ended December 31, 2007. Financing activities during the nine months ended December 31, 2008 consisted primarily of net borrowings under the Company’s credit facilities.

During the course of the Company’s evaluation of the acquisition of MMP, the Company determined that it would shut down its Northglenn, Colorado manufacturing facility and relocate the operations into its Gallaway, Tennessee manufacturing facility. The primary reasons for the plant consolidation were as follows: redundancy of operations; elimination of inter-plant freight costs; increase of manufacturing efficiency and reduction of manufacturing costs. In connection with the consolidation, the Company expects to incur approximately $2,687 of restructuring costs of which $974 is related to severance and $1,713 is related to the shutdown of its Northglenn, Colorado facility and relocation of machinery and equipment and certain employees. The $2,687 was recorded as goodwill and accrued liabilities. During the nine months ended December 31, 2008 the Company incurred approximately $1,551 of expenses in connection with this consolidation leaving a balance of $71 in accrued liabilities. The Company is no longer operating from the Northglenn, Colorado facility and all related operations have been relocated to the Gallaway, Tennessee facility.

On October 17, 2006, the Company entered into a credit agreement with certain lenders and a bank acting as administration agent for the lenders (the “Credit Agreement”). The Credit Agreement, as most recently amended on September 30, 2008, provides for borrowings of $85,000 and is divided into two types of borrowing facilities, (i) a term loan with a principal amount of $65,000, and (ii) revolving credit loans, which amounts may be borrowed, repaid and re-borrowed up to $20,000. The term loan is payable in quarterly installments as follows: $3,250 for each installment date from March 31, 2007 through June 30, 2008, $250 for each installment date from September 30, 2008 through March 31, 2009, $1,625 for each installment date from June 30, 2009 through March 31, 2010, $3,250 for each installment date from June 30, 2010 through March 31, 2011, $5,325 for each installment date from June 30, 2011 through September 30, 2011 and the remaining principal amount outstanding is due on December 31, 2011. As of December 31, 2008, $41,000 is outstanding on the term loan and $13,500 is outstanding on the revolving credit loans. The Company’s availability under the revolving credit loans amounts to $6,500 as of December 31, 2008 and $7,500 as of February 4, 2009.

Both the term loan and revolving credit loans bear interest at the “alternate base rate” plus the applicable margin or at the Company’s option the “LIBOR rate” plus the “applicable margin.” The alternate base rate shall mean a rate per annum equal to the greater of (a) the Prime rate or (b) the Base CD rate in effect on such day plus 1% and (c) the Federal Funds Effective Rate in effect on such day plus  ¹/2 of 1%. “Applicable margin” shall mean with respect to an adjusted LIBOR loan a range of 75 basis points to 150 basis points. With respect to an alternate base rate loan, the applicable margin shall range from 0 basis points to 50 basis points. Effective September 30, 2008, “applicable margin” shall mean with respect to an adjusted LIBOR loan a range of 200 basis points

to 300 basis points. With respect to an alternate base rate loan, the applicable margin shall range from 25 basis points to 125 basis points. The rates for both LIBOR and alternate base rate loans are established quarterly based upon certain agreed upon financial ratios.

28

Table of Contents

Item 2.

Borrowings under this agreement are collateralized by all the assets of the Company, and the agreement contains certain restrictive covenants, which, among other matters, impose limitations with respect to the incurrence of liens, guarantees, merger, acquisitions, capital expenditures, specified sales of assets and prohibits the payment of dividends. The Company is also required to maintain various financial ratios which will be measured quarterly. As of December 31, 2008, the Company is in compliance with all such covenants and financial ratios.

The Company has entered into an agreement to renovate a building purchased in March 2007 located in the Hauppauge, New York area. Renovations are expected to be completed by the end of the fourth quarter of fiscal 2009 at an estimated cost of $7,000. Upon completion, the facility will function as the Company’s corporate headquarters. The Company plans on financing the renovations with cash flow from operations and revolving credit loans. To date, the Company has expended approximately $6,046 with respect to this project, of which $5,626 was expended during the nine months ended December 31, 2008.

The Company believes that the anticipated future cash flow from operations, coupled with its cash on hand and available funds under its revolving credit agreement will be sufficient to meet working capital requirements. Although we have borrowing capacity on our revolving credit loans, cash on hand and anticipate future cash flows from operations, we may be limited in our ability to allocate funds for purposes such as potential acquisitions, capital expenditures, marketing, development and other general corporate purposes. In addition, we may be limited in our flexibility in planning for, or responding to, changing conditions in our business and our industry, making us more vulnerable to general economic downturns and adverse developments in our business.

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

The Company is exposed to interest rate change market risk with respect to its credit facility which is priced based on the alternate base rate of interest plus a spread of up to 1  ¹/4 %, or at LIBOR rate plus a spread of up to 3 %. The spread over the alternate base rate and LIBOR rates is determined based upon the Company’s performance with regard to agreed-upon financial ratios. The Company decides at its sole discretion as to whether borrowings will be at the alternate base rate or LIBOR. At December 31, 2008, $41,000 was outstanding under the credit facility. Changes in the alternate base rates or LIBOR rates during fiscal 2009 will have a positive or negative effect on the Company’s interest expense. During the nine months ended December 31, 2008, the average interest rate on the term loan approximated 4.2%. Each 1% fluctuation in the interest rate will increase or decrease interest expense for the Company by approximately $410 on an annualized basis.

In April 2007, we entered into an interest rate swap agreement to manage our exposure to interest rate changes. The swap effectively converts a portion of our variable rate debt under the credit agreement to a fixed rate, without exchanging the notional principal amounts. At December 31, 2008, we had an interest rate swap agreement (in a notional principal amount of $15,000), which is scheduled to mature in March 2010. Under this agreement, we receive a floating rate based on the LIBOR interest rate, and pay a

29

Table of Contents

Item 3.

fixed rate of 5.02% plus the applicable margin. If, at any time, the swap is determined to be ineffective, in whole or in part, the fair value of the portion of the interest rate swap determined to be ineffective will be recognized as a gain or loss in the statement of operations for the applicable period.

The Company is exposed to interest rate change market risk with respect to the proceeds received from the issuance and sale by the Buncombe County Industrial and Pollution Control Financing Authority Industrial Development Revenue Bonds (the “Bonds”). At December 31, 2008, $1,810 was outstanding for these Bonds. The Bonds bear interest at a variable rate determined weekly. During the nine months ended December 31, 2008, the average interest rate on the Bonds approximated 2.6%. Each 1% fluctuation in interest rates will increase or decrease the interest expense on the Bonds by approximately $18 on an annualized basis.

A significant portion of the Company’s products which are not manufactured domestically are purchased from China. All such purchases are transacted in U.S. dollars. The Company’s financial results, therefore, could be impacted by factors such as changes in foreign currency exchange rates or uncertain economic conditions including the availability of material and the cost of such material.

Beginning in fiscal 2006, the Chinese government began to revalue the Yuan against other currencies, including the U.S. dollar. This ongoing revaluation of exchange rates and removal of certain tax incentives to exporters by the Chinese government has caused the price of many items that are sourced from China to increase, which has adversely impacted our cost of goods sold and profitability. The Company has increased selling prices for certain of these products to recover a portion of the increased cost and will attempt to do so in the future. However, there can be no assurance that the Company will be able to pass along future cost increases, if any, to its customers which could negatively impact our results of operations and financial condition.

Item  4.

Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. As indicated in the certifications in Exhibit 32.1 and 32.2 of this report, our Chief Executive Officer and our Chief Financial Officer, with the assistance of other members of our management, have evaluated our disclosure controls and procedures (as defined in the Securities Exchange Act of 1934 Rules
13a-15(e) and 15d-15(e)). Based upon the evaluation of our disclosure controls and procedures required by Securities Exchange Act Rules 13a-15(b) or 15d-15(b), our Chief Executive Officer and Chief Financial Officer have concluded that as of the end of the period covered by this report, our disclosure controls and procedures were effective for the purpose of ensuring that material information required to be in this quarterly report is made known to them by others on a timely basis.

30

Table of Contents

Item 4.

Our management is responsible for establishing and maintaining adequate internal controls over financial reporting. Our internal control system was designed to provide reasonable assurance to the Company’s management and board of directors regarding the preparation and fair presentation of published financial statements.

All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

Change to Internal Control over Financial Reporting

We are involved in ongoing evaluations of internal controls. In anticipation of the filing of this Form 10-Q, our Chief Executive Officer and Chief Financial Officer, with the assistance of other members of our management, reviewed our internal controls and have determined, based on such review, that there have been no significant changes in internal controls over financial reporting during the nine months ended December 31, 2008 that has materially affected, or is reasonably likely to affect, the Company’s internal control over financial reporting.

31

Table of Contents

MEDICAL ACTION INDUSTRIES INC.

PART II – OTHER INFORMATION

There are no material legal proceedings against the Company or in which any of its property is subject.

Additional Risk Factors

There have been no material changes to the Risk Factors disclosed in Item 1A of our Annual Report on Form 10-K for the year ended March 31, 2008, other than the following:

A significant adverse change in, or failure to comply with, governing regulations could adversely affect the Company’s business.

As a result of an audit by the FDA of our Arden, North Carolina facility, we received a Warning Letter in January 2008. Medical Action prepared a comprehensive response reiterating its commitment to comply with the Current Good Manufacturing Practice requirements. The Company believes that the FDA will re-audit its Arden, North Carolina facility in February 2009. While we have made several changes to our quality systems and to the organizational structure of the Quality and Regulatory Department, the Company’s business and financial condition could be adversely affected if it is found to be out of compliance with governing regulations. In addition, if such regulations are amended to become more restrictive and costly to comply with, the costs of compliance could adversely affect the Company’s business and financial condition.

None

None

None

None

32

Table of Contents

31.1 and 31.2 – Certifications pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002

32.1 and 32.2 – Certifications pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Current Report on Form 8-K dated November 6, 2008, covering Item 7.01 – Results of Operations and Financial Condition and Item 9.01 – Financial Statements and Exhibits

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

33